» Articles » PMID: 23991301

Which Type of Surgery Should Become the Preferred Procedure for Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy or Extended Pleurectomy?

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2013 Aug 31
PMID 23991301
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purposes: Since radiation and chemotherapy have limitations as therapies for malignant pleural mesothelioma (MPM). The type of surgery [extrapleural pneumonectomy (EPP), extended pleurectomy (E/P), and pleurectomy/decortication (P/D)] remains controversial.

Methods: This study involves 76 consecutive patients. 58 of the cases were males (76%) with a median age of 53.17±10.93 years. EPP, E/P, and P/D were performed in 31, 20, and 25 cases, respectively.

Results: The median survival time was 20 months in all patients. Overall, five-year survival rate was 14.3%. The survival rate was significantly better in epithelioid mesothelioma (P=0.049). For EPP cases, the median survival rate was 17 months, and the three-to-five year survival rates were 21% and 17%, respectively. For E/P cases, the median survival rate was 27 months and the three-year and four-year survival rates were 34% and 30%, respectively. For P/D cases, the median survival rate was 15 months and the three-to-five year survival rate was 13% and 0%. There were no statistically significant differences between the three surgical techniques (P=0.088). A comparative analysis indicates only a statistically significant difference in the E/P and P/D comparison (P=0.032). Hospital mortality showed a higher trend in EPP group (EPP: 12.9%, E/P: 0% and P/D: 4%, P=0.145). N2 cases, there were no cases of two-year survival. The survival rate in N2 was comparatively much lower, which was statistically significant (P=0.005). In multivariate analysis, only P/D (OR 0.3, 95% CI: 0.1-0.9, P=0.049) and N2 (OR 1.6, 95% CI: 0.9-2.6, P=0.090) were found to be poor prognostic factors.

Conclusions: E/P could be encouraged to EPP with lower mortality rate and better survival trend in MPM. N2 diseases were negative prognostic factors in MPM.

Citing Articles

Survival Effect of Complete Multimodal Therapy in Malignant Pleural Mesothelioma.

Sayan M, Bas A, Satir Turk M, Ozkan D, Celik A, Kurul I J Chest Surg. 2022; 55(5):405-412.

PMID: 36068966 PMC: 9579847. DOI: 10.5090/jcs.22.037.


Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?.

Ichiki Y, Goto H, Fukuyama T, Nakanishi K J Clin Med. 2020; 9(7).

PMID: 32650433 PMC: 7408715. DOI: 10.3390/jcm9072153.


A case of surgically treated bilateral metachronous malignant pleural mesothelioma.

Bedirhan M, Cansever L, Yoney A, Kocaturk C Turk Gogus Kalp Damar Cerrahisi Derg. 2020; 27(1):121-124.

PMID: 32082839 PMC: 7021381. DOI: 10.5606/tgkdc.dergisi.2019.16162.


A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma.

Opitz I, Weder W Ann Transl Med. 2017; 5(11):237.

PMID: 28706905 PMC: 5497104. DOI: 10.21037/atm.2017.03.88.


Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models.

Nuvoli B, Sacconi A, Cortese G, Germoni S, Murer B, Galati R Oncotarget. 2016; 7(30):47116-47126.

PMID: 27323398 PMC: 5216928. DOI: 10.18632/oncotarget.9964.


References
1.
Tokat A, Kutlay H . [Gene therapy in malignant mesothelioma]. Tuberk Toraks. 2004; 51(4):456-60. View

2.
Zucali P, DE Vincenzo F, Simonelli M, Santoro A . Future developments in the management of malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2009; 9(4):453-67. DOI: 10.1586/era.09.2. View

3.
Rusch V . Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997; 9(4):367-72. View

4.
Edwards J, Abrams K, Leverment J, Spyt T, Waller D, OByrne K . Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000; 55(9):731-5. PMC: 1745842. DOI: 10.1136/thorax.55.9.731. View

5.
Federico R, Adolfo F, Giuseppe M, Lorenzo S, Martino D, Anna C . Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer. 2013; 13:22. PMC: 3722081. DOI: 10.1186/1471-2407-13-22. View